Werewolf Therapeutics reports 2021 net loss $50M, cash $157.5M; IND filings on track

Werewolf Therapeutics, Inc.

Net loss $17.9M in Q4 2021 ($7.4M Q4 2020); full-year loss $50.0M ($15.0M 2020).
Cash $157.5M at Dec 31, 2021 ($92.6M Dec 31, 2020); runway through at least Q2 2023.
R&D expenses $35.3M in 2021 ($16.6M 2020); G&A $14.8M ($5.8M).
IND for WTX-124 expected Q2 2022; IND for WTX-330 early Q3 2022.
Announced clinical trial collaboration with Merck for WTX-124 + Keytruda in solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.